RxTrials Institute Drug Pipeline Alert

UK drugmaker Oxford BioMedica has completed patient enrollment in the Phase III study of TroVax in renal cancer.

The randomized, placebo-controlled, two-arm TRIST study evaluated TroVax in combination with standard-of-care. The company expects to complete final analysis in the first half of 2009.

Sanofi-aventis, Oxford’s TroVax partner, will start a Phase III trial of the therapy in colorectal cancer, according to Mike McDonald, Oxford’s chief medical officer.